Recombinant immunotoxins: new therapeutic agents for cancer treatment.
We have developed new agents for the treatment of cancer by genetically modifying Pseudomonas exotoxin. We have deleted the cell-binding region of Pseudomonas exotoxin and replaced it with various growth factors or the combining regions of antibodies in a single chain form. These new recombinant molecules are called recombinant toxins. Several different types of recombinant toxins have been produced. B3(Fv)-PE38KDEL is a recombinant toxin that kills many different adenocarcinomas and epidermoid carcinomas. The molecule is now undergoing preclinical development.
Pastan
I H
IH
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
D036002:ADP Ribose Transferases; D000818:Animals; D001427:Bacterial Toxins / Q000235:genetics / Q000627:therapeutic use*; D005098:Exotoxins / Q000235:genetics / Q000627:therapeutic use*; D000922:Immunotoxins / Q000235:genetics / Q000627:therapeutic use*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000235:genetics; D014178:Translocation, Genetic; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A